CAP in a 67-Year-Old with COPD: Case Review

1. Slide 1 · Community-Acquired Pneumonia in COPD: A Case Review

   Community-Acquired Pneumonia in COPD: A Case Review

   From presentation to discharge: severity, antibiotic choice and evidence-based duration

   [1, 2]

   Made with Doctoria

   Speaker notes

   Welcome, everyone. Today we will walk through a fictional but very typical case: a 67-year-old man with COPD who presents with community-acquired pneumonia. We will follow him step by step, from the first complaints through the work-up, severity scoring with CURB-65, the choice of empiric antibiotics and his clinical course. At each decision point we will anchor ourselves in the ATS/IDSA 2019 guideline, its 2026 ATS update and supporting systematic reviews. The goal is practical: by the end, you should feel confident about where to treat, what to prescribe, how long to treat and when to escalate.

2. Slide 2 · Case: 67-year-old man with COPD and fever

   Case: 67-year-old man with COPD and fever

   Ex-smoker, 40 pack-years; COPD GOLD 2 on LAMA/LABA

   4 days of fever, purulent sputum and right pleuritic chest pain

   Dyspnoea worse than baseline; no recent hospitalisation or antibiotics

   Comorbidities: hypertension; independent in daily activities

   No prior Pseudomonas or MRSA isolates on record

   02

   Made with Doctoria

   Speaker notes

   Our patient is a 67-year-old ex-smoker with moderate COPD, maintained on a LAMA/LABA combination. He presents with four days of fever, purulent sputum, right-sided pleuritic pain and dyspnoea beyond his usual baseline. Note the details that matter for later decisions: no hospitalisation or intravenous antibiotics in the last 90 days, no previous respiratory isolation of Pseudomonas or MRSA, and he is fully independent. The key differential here is an infective COPD exacerbation versus pneumonia. Pleuritic pain and focal signs push us towards pneumonia, but only imaging will settle it. Practical tip: always document prior microbiology and recent antibiotic exposure at admission.

3. Slide 3 · Work-up confirms right lower lobe pneumonia

   Work-up confirms right lower lobe pneumonia

   Domain	Finding	Interpretation
   Vital signs	T 38.6 °C, HR 104, RR 26/min, BP 128/76, SpO2 89% RA	Hypoxaemic, haemodynamically stable
   Mental status	Alert, oriented	No confusion
   Blood tests	WBC 15.8 ×10⁹/L, CRP 186 mg/L, urea 8.6 mmol/L	Bacterial pattern, raised urea
   Arterial gas (RA)	pH 7.42, PaCO2 5.6 kPa, PaO2 7.6 kPa	Type 1 respiratory failure, no hypercapnia
   Chest X-ray	Right lower lobe consolidation, no effusion	Confirms CAP
   Microbiology	Blood cultures, sputum culture, urinary antigens, viral PCR	Pneumococcal urinary antigen positive

   03

   [1]

   Made with Doctoria

   Speaker notes

   Here is the admission work-up. He is febrile, tachycardic and hypoxaemic at 89% on room air, but normotensive and fully oriented. Inflammatory markers are clearly raised and urea is 8.6 millimoles per litre. The arterial gas is reassuring in a COPD patient: type 1 failure without hypercapnia, which still means controlled oxygen with a target of 88 to 92 percent. The radiograph confirms right lower lobe consolidation. Because he is being admitted, we sent blood and sputum cultures and a respiratory viral PCR; ATS/IDSA reserves routine cultures mainly for severe CAP or resistance risk, so this reflects local practice. The pneumococcal urinary antigen came back positive.

4. Slide 4 · CURB-65 = 2: hospital admission warranted

   CURB-65 = 2: hospital admission warranted

   Criterion	Threshold	Our patient	Point
   Confusion	New disorientation	Alert, oriented	0
   Urea	> 7 mmol/L	8.6 mmol/L	1
   Respiratory rate	≥ 30/min	26/min	0
   Blood pressure	SBP < 90 or DBP ≤ 60 mmHg	128/76 mmHg	0
   Age	≥ 65 years	67 years	1

   04

   [1, 3, 4]

   Made with Doctoria

   Speaker notes

   Let us score him. Confusion: no. Urea above 7: yes, one point. Respiratory rate 30 or more: no, he is at 26. Blood pressure: normal. Age 65 or over: yes, one point. That gives CURB-65 of 2, which places him in an intermediate-risk group where hospital-based care is usually appropriate. Remember that ATS/IDSA 2019 prefers the Pneumonia Severity Index over CURB-65 for deciding outpatient treatment, and that scores never replace judgement. Here, hypoxaemia alone mandates admission regardless of the score. Also screen for severe CAP using the ATS/IDSA major and minor criteria; he meets none of the major ones.

5. Slide 5 · CURB-65 stratifies 30-day mortality steeply

   CURB-65 stratifies 30-day mortality steeply

   0.7%

   30-day mortality with CURB-65 score 0

   3%

   30-day mortality with score 2, our patient

   17%

   30-day mortality with score 3

   41.5%

   30-day mortality with score 4

   05

   [3, 4, 5]

   Made with Doctoria

   Speaker notes

   These figures come from the original derivation study by Lim and colleagues in Thorax, based on just over a thousand hospitalised patients. Mortality is low at scores 0 and 1, rises modestly at 2, and then jumps sharply from 3 upwards, reaching 57 percent at score 5. Our patient sits at around 3 percent. In elderly inpatients, a 2024 comparison found PSI had the best discrimination and negative predictive value for mortality, while CURB-65 and SMART-COP remain practical at the bedside. The practical message: use CURB-65 quickly, but reassess oxygenation, comorbidity and functional status, which scores do not capture well.

6. Slide 6 · COPD raises resistance risk, but not here

   COPD raises resistance risk, but not here

   Evidence on drug-resistant pathogens

   Meta-analysis: COPD and chronic lung disease are risk factors

   Prior DRP colonisation, recent antibiotics and hospitalisation also predict

   Severe respiratory failure needing early ventilation increases risk

   Overuse of broad-spectrum agents drives harm and resistance

   Applied to our patient

   No prior Pseudomonas or MRSA respiratory isolates

   No hospitalisation or IV antibiotics in past 90 days

   Non-severe CAP, ambulatory, independent

   Decision: standard regimen, no anti-pseudomonal or MRSA cover

   06

   [1, 6]

   Made with Doctoria

   Speaker notes

   COPD patients make us nervous about resistant organisms, and with some reason. A 2025 meta-analysis identified COPD among eleven risk factors for drug-resistant pathogens in CAP, alongside prior colonisation, recent antibiotics, hospitalisation and nursing home residence. However, ATS/IDSA 2019 abandoned the healthcare-associated pneumonia concept and recommends extended cover for MRSA or Pseudomonas mainly when there is prior respiratory isolation, or recent hospitalisation with parenteral antibiotics plus locally validated risk factors. Our patient has none of these and his CAP is non-severe. So COPD alone does not justify piperacillin-tazobactam here. Tip: if you do start broad cover, obtain cultures so you can de-escalate.

7. Slide 7 · Empiric therapy for non-severe inpatient CAP

   Empiric therapy for non-severe inpatient CAP

   Option	Agents and doses	Comment
   β-lactam + macrolide	Ceftriaxone 1–2 g IV daily + azithromycin 500 mg daily	Chosen regimen for our patient
   Alternative β-lactams	Ampicillin-sulbactam 1.5–3 g q6h, cefotaxime 1–2 g q8h, ceftaroline 600 mg q12h	Combine with macrolide
   Macrolide alternative	Clarithromycin 500 mg twice daily	Check QT and interactions
   Respiratory fluoroquinolone	Levofloxacin 750 mg daily or moxifloxacin 400 mg daily	Monotherapy; weigh tendon, QT, C. difficile risk

   07

   [1, 7]

   Made with Doctoria

   Speaker notes

   For non-severe inpatient CAP without resistance risk factors, ATS/IDSA 2019 gives two strongly recommended options: a β-lactam plus a macrolide, or a respiratory fluoroquinolone alone. We chose ceftriaxone 1 gram daily plus azithromycin 500 milligrams daily. Fluoroquinolone monotherapy is equally effective, but in an older patient we weigh the risks of tendinopathy, QT prolongation, dysglycaemia and Clostridioides difficile. In severe CAP, the guideline recommends a β-lactam plus either a macrolide or a fluoroquinolone. Practical tip: give the first dose promptly in the emergency department, and check the ECG before macrolides in patients on QT-prolonging drugs.

8. Slide 8 · Rapid stability allowed oral step-down by day 3

   Rapid stability allowed oral step-down by day 3

   Days 1–2

   Controlled O2, target SpO2 88–92%; no hypercapnia on repeat gas

   IV ceftriaxone + azithromycin; bronchodilators continued

   Afebrile by 48 h, RR and HR normalising

   Days 3–5

   Clinically stable, eating, SpO2 92% on room air

   Switched to oral amoxicillin; azithromycin course completed

   Discharged day 4; total antibiotic duration 5 days

   08

   [1, 2, 8, 9]

   Made with Doctoria

   Speaker notes

   His course was uncomplicated. Under controlled oxygen he never developed hypercapnia, and he was afebrile within 48 hours. By day 3 he met stability criteria: normal vital signs, adequate oral intake, normal mentation and saturations acceptable on room air. With pneumococcus confirmed, we stepped down to oral amoxicillin and completed a 5-day total course. ATS/IDSA recommends at least 5 days, guided by clinical stability, and an umbrella review in Lancet Infectious Diseases supports 5 days for non-ICU CAP. Procalcitonin can support stopping antibiotics, but should not decide whether to start them. Routine systemic steroids are not indicated in non-severe CAP.

9. Slide 9 · Take-home points for CAP in COPD

   Take-home points for CAP in COPD

   Combine CURB-65 or PSI with oxygenation and clinical judgement

   COPD alone does not mandate anti-pseudomonal or MRSA cover

   β-lactam plus macrolide or respiratory fluoroquinolone for non-severe inpatients

   Target SpO2 88–92% and recheck gases if hypercapnia risk

   Five days suffice once clinically stable; step down orally early

   09

   [1, 3, 6, 8]

   Made with Doctoria

   Speaker notes

   Let me summarise. First, severity scores are tools, not decisions: integrate them with oxygenation, comorbidity and function. Second, COPD increases resistance risk at population level, but empiric broad-spectrum cover should follow specific risk factors such as prior isolates or recent hospitalisation with IV antibiotics. Third, stick to guideline-concordant regimens. Fourth, in COPD use controlled oxygen. Fifth, five days is enough for most non-ICU patients once stable. Before discharge, review vaccination status for pneumococcus and influenza, reinforce inhaler technique, and arrange follow-up. A routine follow-up chest radiograph is not needed if symptoms resolve, unless malignancy risk prompts it.

10. Slide 10 · References

    References

    1. 1.Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019. doi:10.1164/rccm.201908-1581ST
    2. 2.Jones BE, Ramirez JA, Oren E, et al. Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2026. doi:10.1164/rccm.202507-1692ST
    3. 3.Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003. doi:10.1136/thorax.58.5.377
    4. 4.Kolditz M, Braeken D, Ewig S, et al. Severity Assessment and the Immediate and Long-Term Prognosis in Community-Acquired Pneumonia. Semin Respir Crit Care Med. 2016. doi:10.1055/s-0036-1592127
    5. 5.Huang L, Weng B, Gu X, et al. Performance of various pneumonia severity models for predicting adverse outcomes in elderly inpatients with community-acquired pneumonia. Clin Microbiol Infect. 2024. doi:10.1016/j.cmi.2024.07.008
    6. 6.Nakagawa N, Katsurada M, Fukuda Y, et al. Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis. Eur Respir Rev. 2025. doi:10.1183/16000617.0183-2024
    7. 7.Olson G, Davis AM. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. JAMA. 2020. doi:10.1001/jama.2019.21118
    8. 8.Kuijpers SME, Buis DTP, Ziesemer KA, et al. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review. Lancet Infect Dis. 2025. doi:10.1016/S1473-3099(24)00456-0
    9. 9.Schuetz P, Bolliger R, Merker M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Rev Anti Infect Ther. 2018. doi:10.1080/14787210.2018.1496331

    10

    Made with Doctoria

11. Slide 11 · Questions?

    Questions?

    Treat the risk factors you document, not the label: COPD alone does not mean broad-spectrum

    Made with Doctoria

    Speaker notes

    Thank you for your attention. I hope this case showed how a structured approach turns a common admission into a series of clear, evidence-based decisions: confirm the diagnosis, stratify severity, assess resistance risk objectively, choose a guideline-concordant regimen, and stop at five days once the patient is stable. I would be happy to take questions, particularly about difficult scenarios such as COPD patients with previous Pseudomonas isolates, those requiring non-invasive ventilation, or cases where viral testing is positive. Please share your own local practice and experiences too.

This presentation was generated automatically to show what Doctoria can do and has not been reviewed as clinical guidance. Clinical cases in the examples are fictional.